Firoozeh Sahebi, M.D.
Hematologist
4.9 (59 RATINGS)
Clinical Expertise
Bone Marrow Transplantation
Appointments
Professor, Department Of Hematology & Hematopoietic Cell Transplantation
Research Teams
Firoozeh Sahebi, M.D., is a board-certified hematologist specializing in Bone Marrow Transplant and Cancer Cellular Immunotherapy. She is also a member of the City of Hope/Kaiser Bone Marrow Transplantation Team.
Dr. Sahebi obtained her medical degree from School of Medicine at Tehran University. She completed her residency in Internal Medicine at Nassau County Medical Center in East Meadow, NY. She then moved on to complete fellowships in Hematology/Oncology at Columbia University and UCLA Medical Center.
She is a member of multiple institutional committees at City of Hope and Southern California Kaiser Permanente. She has published several peer reviewed journals and presented her research at American Society of Hematology and European Society for Blood and Marrow Transplantation meetings.
Dr. Sahebi enjoys spending time with her family, painting, yoga and her book club.
American Board of Hematology
1987, M.D., Tehran University, School of Medicine, Tehran, Iran
1992-1994, Divisions of Hematology /Oncology, UCLA Medical Center, Los Angeles, CA
1991-1992, Divisions of Hematology/ Oncology, Columbia University, College of Physicians & Surgeons, Presbyterian Hospital, New York, NY
1988-1991, Nassau County Medical Center, Affiliate of State University of New York at Stony Brook, New York, NY
1998-present, Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
1994-present, Staff Physician, Division of Bone Transplantation and Hematology/Oncology, Kaiser Hospital, Los Angeles, CA
11/2013, Walter Lusk Award Distinguished Physician Award for excellence in compassionate care and outstanding communication with patients
1994-1999, UCLA Teaching Appreciation Award
- Sahebi F, Eikema D, Koster L, Kröger N, Meijer E, Choi G, Rovira M, Koc Y, Angelucci E, Blaise D, Tarella C, et al. Post-Transplant Cyclophosphamide for Graft Vs Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison By Donor Type; A Study from the Chronic Malignancies Working Party of the EBMT, Blood (2020) 136 (Supplement 1): 1–2. 10.1182/blood-2020-137789
- Giralt S, Costa LJ, Maloney D, Krishnan A, Fei M, Antin JH, Brunstein C, Geller N, Goodman S, Hari P, Logan B, Lowsky R, Qazilbash MH, Sahebi F, et al. Tandem Autologous-Autologous versus Autologous-Page 3 of 7
- Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial. Biol Blood Marrow Transplant. 2020 Apr;26(4):798-804. doi: 10.1016/j.bbmt.2019.11.018. Epub 2019 Nov 19.Biol Blood Marrow Transplant. 2020. PMID: 31756536
- Herrera A, Chen L, Nieto Y, Holmberg L, Johnston P, Mei M, Popplewell L, Armenian S, Cao T, Farol L, Sahebi F, et al. Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma Blood (2020) 136 (Supplement 1): 19–20. Oral and Poster Abstracts Pourmoussa AM, Spielberger R, Cai J, Khoshbin O, Farol L, Cao T, Sahebi F. , et al. Predictive Factors for Early Relapse in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplant. Perm J. 2019;23:19.012. doi: 10.7812/TPP/19.012. Epub 2019 Oct 11.Perm J. 2019. PMID: 31926575
- Giralt S, Costa LJ, Maloney D, Krishnan A, Fei M, Antin JH, Brunstein C, Geller N, Goodman S, Hari P, Logan B, Lowsky R, Qazilbash MH, Sahebi F, Somlo G, Rowley S, Vogl DT, Vesole DH, Pasquini M, Stadtmauer E. Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma: Long-term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial. Biol Blood Marrow Transplant. 2019 Nov 19. pii: S1083-8791(19)30785-2. doi: 10.1016/j.bbmt.2019.11.018. [Epub ahead of print] PMID: 31756536
- Maffini E, Storer BE, Sandmaier BM, Bruno B, Sahebi F, Shizuru JA, Chauncey TR, Hari P, Lange T, Pulsipher MA, McSweeney PA, Holmberg L, Becker PS, Green DJ, Mielcarek M, Maloney DG, Storb R. Long-term Follow Up of Tandem Autologous-allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Haematologica. 2019 Feb;104(2):380-391. doi: 10.3324/haematol.2018.200253. [Epub 2018 Sep 27] PMID:30262560
- Sahebi F, Garderet L, Kanate AS, Eikema DJ, Knelange NS, Alvelo OFD, Koc Y, Blaise D, Bashir Q, Moraleda JM, Dreger P, Sanchez JF, Ciurea S, Schouten H, Shah NN, Verbeek M, Rösler W, Diez-Martin JL, Schoenland S, D'Souza A, Kröger N, Hari P. Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report. Biol Blood Marrow Transplant. 2018 Sep 20. pii: S1083-8791(18)30575-5. doi: 10.1016/j.bbmt.2018.09.018. [Epub ahead of print] PMID:30243581
- Sahebi F, Iacobelli S, Sbianchi G, Koster L, Blaise D, Reményi P, Russell NH, Ljungman P, Kobbe G, Apperley J, Trneny M, Krejci M, Wiktor-Jedrzejczak W, Sanchez JF, Schaap N, Isaksson C, Lenhoff S, Browne P, Scheid C, Wilson KMO, Yakoub-Agha I, Muñiz SG, Schönland S, Morris C, Garderet L, Kröger N. Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents. Biol Blood Marrow Transplant. 2018 Jan 12. pii: S1083-8791(18)30021-1. doi: 10.1016/j.bbmt.2018.01.006. [Epub ahead of print] PMID:29339268
- Herrera AF, Palmer J, Martin P, Armenian S, Tsai NC, Kennedy N, Sahebi F, Cao T, Budde LE, Mei M, Siddiqi T, Popplewell L, Rosen S, Kwak L, Nademanee A, Forman S, Chen R. Autologous Stem Cell Transplantation After Second Line Brentuximab Vedotin in Relapsed or Refractory Hodgkin Lymphoma. Ann Oncol. 2017 Dec 20. doi: 10.1093/annonc/mdx791. [Epub ahead of print] PMID:29272364 Krishnan A, Kapoor P, Palmer JM, Tsai NC, Kumar S, Lonial S, Htut M, Karanes C, Nathwani N, Rosenzweig M, Sahebi F, Somlo G, Duarte L, Sanchez JF, Auclair D, Forman SJ, Berdeja JG. Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. Leukemia. 2017 Dec 18. doi: 10.1038/leu.2017.352. [Epub ahead of print] PMID: 29249822 Page 4 of 7
- Stein A, Palmer J, Tsai NC, Al Malki MM, Aldoss I, Ali H, Aribi A, Farol L, Karanes C, Khaled S, Liu A, O'Donnell M, Parker P, Pawlowska A, Pullarkat V, Radany E, Rosenthal J, Sahebi F, Salhotra A, Sanchez JF, Schultheiss T, Spielberger R, Thomas SH, Snyder D, Nakamura R, Marcucci G, Forman SJ, Wong J. Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia. Biol Blood Marrow Transplant. 2017 Apr;23(4):618-624. doi: 10.1016/j.bbmt.2017.01.06
Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with 5 stars being the highest.
Ratings
5.0
Show respect for what you say
5.0
Provider listen carefully to you
4.9
Recommend this provider office
4.9
Provider explain in way you understand
4.8
Spend enough time with you
4.8
Rate provider 0-10
4.7
Know important info medical history
Reviews
11/14/22
During my entire visit I was impressed with the efficiency and care that I witnessed. - Verified patient
08/28/22
I will definitely recommend this hospital because it's the best of the best! - Verified patient
08/27/22
I've known Dr. Sahebi for 15 years. She had been with me during my entire journey combating multiple myeloma. I probably wouldn't be here today if not for her. - Verified patient
05/25/22
For me very excellent work. I am very satisfied, very good work. - Verified patient
03/25/22
Dr. Sahebi has been my BMT doctor for the last 14 years - She is the BEST. - Verified patient